21 February 2024 - Britain's health regulator said on Wednesday it had revoked a conditional marketing authorisation for Novartis' sickle cell disease drug, Adakveo.

The decision follows the Swiss drug maker's move to recall a batch of the drug after the MHRA said it no longer considered the treatment's benefits to risk balance favourable.

Read Reuters article